Latest Solutions Focus on Improving AR Recovery and Denials ManagementCHICAGO, April 14, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the...
Major paradigm shift incorporates five-year risk assessment and identifies increased-risk women beginning at age 35 BOSTON, April 14, 2026 (GLOBE...
Partnership Extends IM8’s Mission Beyond Premium Nutrition to Address Malnutrition Among the World’s Most Vulnerable Populations Long-Term Goal to Impact...
- Top-line data expected in mid-2027; Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class...
DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- GeneCentric, a company making precision medicine more precise by bringing gene expression...
CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine...
Enhancing emergency triage imaging with Nanox.ARC to improve efficiency and lower radiation dose Collaboration expands clinical evidence base of Nanox.ARC...
On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase...
Adds dedicated business development leadership to support Tempest’s strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering...
Establishes framework targeting multi-product commercialization across high-growth health and wellness categories with scalable revenue potentialWoodland, CA, April 14, 2026 (GLOBE...
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April...
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology...
Mean time to graft reduced to 13.6 days vs. 33.2 days real-world benchmark (~20 day reduction)Median time to graft of...
Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech...
FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE...
Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic...
FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq:...
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage...
LONDON and PHILADELPHIA, April 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical...